Technological innovation is a long-term behavior. Since its establishment, Hunan Usel Pharmaceutical has always adhered to the path of independent innovation, and its raw materials and key production processes have independent intellectual property rights. The company has four major technology platforms: SEQUENCE, MAP, PAIR, and CHARATERIZE, integrating computational biology and machine learning technologies to mine immune response information from clinical samples.
SEQUENCE: Decoding single stranded gene information of TCR and BCR through NGS to obtain data on the number and diversity of T and B cell clones in the tested blood sample. The amplification bias encountered in multiple PCR amplification before sequencing often leads to significant differences between sequencing results and the true situation, making it difficult to achieve quantitative detection. To address this challenge, Adaptive constructed a computational system that can simulate the rearrangement process of immune receptor V and J gene fragments, detecting whether specific primers have been amplified too little or too much, and diluting the primer concentration to dynamically correct for preference differences in amplification.
MAP: The company's own MIRA technology can simultaneously match and pair thousands of antigens with TCR. The process is to first form an antigen library of antigens that need to be paired, including various types of antigens such as novel, tumor related, viral, bacterial, and autoimmune antigens, and incubate them with immune cells from multiple donor individuals. Then, specific biological targets are used to sort immune cells. Finally, the pairing analysis between antigens and immune receptors is completed through sequencing analysis of T cell clones, And form a database of the corresponding relationship between diseases and immune receptors. The data information formed by MAP can be combined with SEQUENCE technology to analyze the immune antigen data of the subjects, compare it with the MAP database, and ultimately predict which type of disease the subjects' immune system is exposed to or resisting. Its detection sensitivity is thousands of times higher than the widely used enzyme-linked immunosorbent assay.
PAIR: Immune receptors are composed of two chains, and the genes encoding the two chains are located on different chromosomes, so matching the gene information of the two chains is very difficult. The pairSEQ system developed by Adaptive can achieve accurate pairing of two Y-shaped immune receptor chains, and its throughput is much higher than that of single cell sequencing. Based on the large amount of receptor single chain information obtained by SEQUENCE, AI technology is used for single chain pairing to achieve immune receptor reconstruction, and thus discover and develop new receptors with therapeutic functions.
CHARACTERIZE: Functional validation of the discovered novel receptors in terms of binding power, toxicity, and safety, ultimately leading to the development of TCR mediated cell therapy. At present, Adaptive has identified 1200 TCRs with single antigen specificity, which can bind to 600 different clinically relevant antigens and are in the process of functional verification at different stages.
At present, Hunan Usher Pharmaceutical Co., Ltd. has gradually formed the prototype of the entire pharmaceutical industry chain. The company will continue to invest 300 million yuan in the next three years to expand its business model, further develop the domestic technology and pharmaceutical market, and build a pharmaceutical technology industry park: to build a pharmaceutical industry chain that integrates GMP pharmaceutical production enterprises, GSP pharmaceutical wholesale companies, pharmaceutical research institutes, self owned hospitals, doctor group companies, and internet healthcare, and to promote the integration of the pharmaceutical industry in the Yangtze River Basin.
Hunan Uther Pharmaceutical Co., Ltd. aims to become a demonstration point for the technology and pharmaceutical industry in Hunan region, and then cover South and North China regions, and even achieve the main version listing in China!